Products for Research Use Only
RegisterLogin

Cbl-b-IN-29

CAT: 0804-HY-179575Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-179575Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research[1].
CAS Number
3070411-10-5
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; Interleukin Related
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Field of Research
Cancer; Inflammation/Immunology
Smiles
CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1
Molecular Formula
C30H34FN5O
Molecular Weight
499.62
References & Citations
[1]Han Wang, et al. A unified language model bridging de novo and fragment-based 3D molecule design delivers potent CBL-B inhibitors for cancer treatment. bioRxiv, 2025.11.13.688260
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-159615Cbl-b-IN-21
HY-163194Cbl-b-IN-16
HY-169005Cbl-b-IN-27
HY-158174Cbl-b-IN-20
HY-156764Cbl-b-IN-8
HY-156768-01Cbl-b-IN-12
HY-155120-01Cbl-b-IN-5
HY-173311Cbl-b-IN-28
HY-158171Cbl-b-IN-17
HY-156763Cbl-b-IN-7

Alternative Products

CatalogName
GTR19273810-01Cbl-b-IN-29
sc-376409Cbl-b (B-5)
BA7372-1Cbl-b-IN-1
BA7392-25Cbl-b-IN-5
T209801-01Cbl-b-IN-20
T209659-01Cbl-b-IN-17
T209172-01Cbl-b-IN-16
T200325-01Cbl-b-IN-26
T79900-01Cbl-b-IN-13
T79899-01Cbl-b-IN-12

Popular Products